Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP2020
- Development stage
- Phase 1
- Lead developer
- Astellas Pharma
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
ASP2020 is an investigational allogeneic cell therapy comprising human stem cell-derived retinal pigment epithelial (RPE) cells. Developed by the Astellas Institute for Regenerative Medicine (AIRM), it is designed for the treatment of Stargardt-type macular dystrophies, including Stargardt disease (STGD). The therapy is administered as a single subretinal injection, with the goal of replacing damaged or lost RPE cells in the macula. By replenishing the RPE layer, ASP2020 aims to restore the metabolic and structural support necessary for photoreceptor survival, potentially halting or reversing the progression of central vision loss in patients with these inherited retinal conditions.
Beyond the preview
Go deeper on ASP2020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASP2020.